Skip to main content
Top
Published in: Journal of Community Health 1/2014

01-02-2014 | Original Paper

Assessment of Tdap Administration Rates from 2009 to 2012 at a Large Urban Nonteaching Hospital

Authors: Eric Wombwell, Whitney Palecek, Elizabeth Englin, Tinh Nguyen

Published in: Journal of Community Health | Issue 1/2014

Login to get access

Abstract

Due to the significant rise in pertussis cases reported in 2012, these authors investigated the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine administration at our institution from 2009 to 2012 to determine if changes in prescribing practices reflected published updates from the Advisory Committee on Immunization Practices (ACIP). A single large, urban, private, non-teaching hospital. Documented Tdap vaccines administered from January 2009 through December 2012 were retrieved using an electronic data pull. The incidence of Tdap vaccine administration was reported as number of events per 1,000 patient visits. This data pull served to provide the longitudinal context to prescribing pattern changes at our facility, which were then compared to ACIP vaccination recommendation changes. Tdap administrations increased from 1,365 vaccinations in 2009 to 3,048 vaccinations in 2012. Tdap vaccine administration increased significantly each successive year from 2009 to 2012 from 23.96 ± 1.25 to 47.15 ± 1.63 vaccines per 1,000 patient visits to the facility. Confidence intervals did not overlap for consecutive years representing statistically significant differences between vaccination rates from year to year. Review of Tdap administrations demonstrates a clear and significant increase over consecutive years from 2009 to 2012. Over this time period there were no institutional initiatives aimed at increasing appropriate Tdap use at our institution. This study suggests a correlation between ACIP vaccination recommendations and provider prescribing of Tdap, although no definitive association can be made.
Literature
1.
go back to reference Crowcroft, N. S., & Pebody, R. G. (2006). Recent developments in pertussis. Lancet, 367(9526), 1926–1936.PubMedCrossRef Crowcroft, N. S., & Pebody, R. G. (2006). Recent developments in pertussis. Lancet, 367(9526), 1926–1936.PubMedCrossRef
2.
go back to reference Mattoo, S., & Cherry, J. D. (2005). Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella species. Clinical Microbiology Reviews, 18(2), 326–382.PubMedCentralPubMedCrossRef Mattoo, S., & Cherry, J. D. (2005). Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella species. Clinical Microbiology Reviews, 18(2), 326–382.PubMedCentralPubMedCrossRef
3.
go back to reference Gall, S. (2012). Prevention of pertussis, tetanus, and diphtheria among pregnancy postpartum women and infants. Clinical Obstetrics and Gynecology, 55(2), 498–509.PubMedCrossRef Gall, S. (2012). Prevention of pertussis, tetanus, and diphtheria among pregnancy postpartum women and infants. Clinical Obstetrics and Gynecology, 55(2), 498–509.PubMedCrossRef
4.
go back to reference Eidlitz-Markus, T., Mimouni, M., & Zeharia, A. (2007). Pertussis symptoms in adolescents and children versus infants: the influence of vaccination and age. Clinical Pediatrics (Philadelphia), 46(8), 718–723.CrossRef Eidlitz-Markus, T., Mimouni, M., & Zeharia, A. (2007). Pertussis symptoms in adolescents and children versus infants: the influence of vaccination and age. Clinical Pediatrics (Philadelphia), 46(8), 718–723.CrossRef
5.
go back to reference Stojanov, S., Liese, J., & Belohradsky, B. H. (2000). Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection. Infection, 28(2), 106–110.PubMedCrossRef Stojanov, S., Liese, J., & Belohradsky, B. H. (2000). Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection. Infection, 28(2), 106–110.PubMedCrossRef
6.
go back to reference Vitek, C. R., Pascual, F. B., Baughman, A. L., & Murphy, T. V. (2003). Increase in deaths from pertussis among very young infants in the Unites States in the 1990s. Pediatric Infectious Disease Journal, 22, 628.PubMed Vitek, C. R., Pascual, F. B., Baughman, A. L., & Murphy, T. V. (2003). Increase in deaths from pertussis among very young infants in the Unites States in the 1990s. Pediatric Infectious Disease Journal, 22, 628.PubMed
7.
go back to reference CDC. (2006). Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Morbidity and Mortality Weekly Report, 55(RR17), 1–33. CDC. (2006). Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Morbidity and Mortality Weekly Report, 55(RR17), 1–33.
8.
go back to reference CDC. (2013) Notifiable diseases and mortality tables. Morbidity and Mortality Weekly Report, 61(52), ND-719–ND-732. CDC. (2013) Notifiable diseases and mortality tables. Morbidity and Mortality Weekly Report, 61(52), ND-719–ND-732.
9.
go back to reference National Communicable Disease Center. (1968). Morbidity and mortality annual supplement Summary 1967: reported incidence of notifiable diseases in the United States, 1967, whooping cough (pertussis), 1943–1967. U.S. Department of Health, Education, and Welfare, 16(53), 1–60. National Communicable Disease Center. (1968). Morbidity and mortality annual supplement Summary 1967: reported incidence of notifiable diseases in the United States, 1967, whooping cough (pertussis), 1943–1967. U.S. Department of Health, Education, and Welfare, 16(53), 1–60.
10.
go back to reference Blumberg, D. A., Mink, C. M., Cherry, J. D., et al. (1991). Comparison of acellular and whole-cell pertussis-component diphtheria–tetanus–pertussis vaccines in infants. The APDT Vaccine Study Group. Journal of Pediatrics, 119(2), 194–204.PubMedCrossRef Blumberg, D. A., Mink, C. M., Cherry, J. D., et al. (1991). Comparison of acellular and whole-cell pertussis-component diphtheria–tetanus–pertussis vaccines in infants. The APDT Vaccine Study Group. Journal of Pediatrics, 119(2), 194–204.PubMedCrossRef
11.
go back to reference Greco, D., Salmaso, S., Mastrantonio, P., et al. (1996). A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine, 334(6), 341–348.PubMedCrossRef Greco, D., Salmaso, S., Mastrantonio, P., et al. (1996). A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New England Journal of Medicine, 334(6), 341–348.PubMedCrossRef
12.
go back to reference CDC. (1997). Use of acellular pertussis vaccines among infants and young children recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 46(RR-7),1–25. CDC. (1997). Use of acellular pertussis vaccines among infants and young children recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 46(RR-7),1–25.
14.
go back to reference Lam, C., Octavia, S., Bahrame, Z., Sintchenko, V., Gilbert, G. L., & Lan, R. (2012). Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis. Infection, Genetics, and Evolution, 12, 492–495.CrossRef Lam, C., Octavia, S., Bahrame, Z., Sintchenko, V., Gilbert, G. L., & Lan, R. (2012). Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis. Infection, Genetics, and Evolution, 12, 492–495.CrossRef
15.
go back to reference Klein, N. P., Bartlett, J., Rowhani-Rahbar, A., Fireman, B., & Baxter, R. (2012). Waning protection after fifth dose of acellular pertussis vaccine in children. New England Journal of Medicine, 367(11), 1012–1019.PubMedCrossRef Klein, N. P., Bartlett, J., Rowhani-Rahbar, A., Fireman, B., & Baxter, R. (2012). Waning protection after fifth dose of acellular pertussis vaccine in children. New England Journal of Medicine, 367(11), 1012–1019.PubMedCrossRef
16.
go back to reference CDC. (2012). National and state vaccination coverage among adolescents aged 13–17 years-United States, 2011. Morbidity and Mortality Weekly Report, 61(34), 671–677. CDC. (2012). National and state vaccination coverage among adolescents aged 13–17 years-United States, 2011. Morbidity and Mortality Weekly Report, 61(34), 671–677.
17.
go back to reference Fine, P., Eames, K., & Heymann, D. L. (2011). “Herd immunity”: A rough guide. Clinical Infectious Diseases, 52(7), 911–916.PubMedCrossRef Fine, P., Eames, K., & Heymann, D. L. (2011). “Herd immunity”: A rough guide. Clinical Infectious Diseases, 52(7), 911–916.PubMedCrossRef
18.
go back to reference Forsyth, K. D., Campins-Marti, M., Caro, J., Cherry, J. D., Greenberg, D., & Guiso, N. (2004). New pertussis vaccination strategies beyond infancy: Recommendations by the global pertussis initiative. Clinical Infectious Diseases, 39, 1802–1809.PubMedCrossRef Forsyth, K. D., Campins-Marti, M., Caro, J., Cherry, J. D., Greenberg, D., & Guiso, N. (2004). New pertussis vaccination strategies beyond infancy: Recommendations by the global pertussis initiative. Clinical Infectious Diseases, 39, 1802–1809.PubMedCrossRef
19.
go back to reference CDC. (2012). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older-advisory committee on immunization practices (ACIP), 2012. Morbidity and Mortality Weekly Report, 61(25), 468–470. CDC. (2012). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older-advisory committee on immunization practices (ACIP), 2012. Morbidity and Mortality Weekly Report, 61(25), 468–470.
23.
go back to reference CDC. (2013). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women—Advisory Committee on Immunization Practices (ACIP), 2012. Morbidity and Mortality Weekly Report, 62(07), 131–135. CDC. (2013). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women—Advisory Committee on Immunization Practices (ACIP), 2012. Morbidity and Mortality Weekly Report, 62(07), 131–135.
24.
go back to reference CDC. (2011). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. Morbidity and Mortality Weekly Report, 60(1), 13–15. CDC. (2011). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. Morbidity and Mortality Weekly Report, 60(1), 13–15.
25.
go back to reference CDC. (2011). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant < 12 months—Advisory Committee on Immunization Practices (ACIP), 2011. Morbidity and Mortality Weekly Report, 60(41), 1424–1426. CDC. (2011). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant < 12 months—Advisory Committee on Immunization Practices (ACIP), 2011. Morbidity and Mortality Weekly Report, 60(41), 1424–1426.
26.
go back to reference Witt, M. A., Katz, P. H., & Witt, D. J. (2012). Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clinical Infectious Diseases, 54(12), 1730–1735.PubMedCrossRef Witt, M. A., Katz, P. H., & Witt, D. J. (2012). Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clinical Infectious Diseases, 54(12), 1730–1735.PubMedCrossRef
27.
go back to reference Rozenhaum, M. H., DeVries, R., Le, H. H., & Postma, M. J. (2012). Modeling the impact of extended vaccination strategies on the epidemiology of pertussis. Epidemiology and Infection, 140, 1503–1514.CrossRef Rozenhaum, M. H., DeVries, R., Le, H. H., & Postma, M. J. (2012). Modeling the impact of extended vaccination strategies on the epidemiology of pertussis. Epidemiology and Infection, 140, 1503–1514.CrossRef
28.
go back to reference Bailleux, F., Coudeville, L., Kolenc-Saban, A., Bevilacqua, J., Barreto, L., & Andre, P. (2008). Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine, 26, 3903–3908.PubMedCrossRef Bailleux, F., Coudeville, L., Kolenc-Saban, A., Bevilacqua, J., Barreto, L., & Andre, P. (2008). Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine, 26, 3903–3908.PubMedCrossRef
29.
go back to reference Halperin, S. A., Scheifele, D., De Serres, G., Noya, F., & Meekison, W. (2012). Zickler, et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine, 30, 974–982.PubMedCrossRef Halperin, S. A., Scheifele, D., De Serres, G., Noya, F., & Meekison, W. (2012). Zickler, et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine, 30, 974–982.PubMedCrossRef
30.
go back to reference Rendi-Wagner, P., Paulke-Korinek, M., Stanek, G., Khanakah, G., & Kollaritsch, H. (2007). Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatric Infectious Diseases Journal, 26(9), 806–810.CrossRef Rendi-Wagner, P., Paulke-Korinek, M., Stanek, G., Khanakah, G., & Kollaritsch, H. (2007). Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatric Infectious Diseases Journal, 26(9), 806–810.CrossRef
Metadata
Title
Assessment of Tdap Administration Rates from 2009 to 2012 at a Large Urban Nonteaching Hospital
Authors
Eric Wombwell
Whitney Palecek
Elizabeth Englin
Tinh Nguyen
Publication date
01-02-2014
Publisher
Springer US
Published in
Journal of Community Health / Issue 1/2014
Print ISSN: 0094-5145
Electronic ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-013-9736-3

Other articles of this Issue 1/2014

Journal of Community Health 1/2014 Go to the issue